GlassScriptPhysician profile
Lily Liu
NPI 1144728502
$4,720.15
in general payments reported to CMS, 2019-2025
23 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.11 · 2022: $599 · 2023: $1,084 · 2024: $2,474 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,050.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,766.84 | 2021-2024 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $680.56 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $397.80 | 2022-2024 | |
| Glaxosmithkline, LLC. | $383.64 | 2022-2025 | Benlysta |
| Ucb, INC. | $242.02 | 2023-2025 | Bimzelx, Cimzia |
| Alexion Pharmaceuticals, INC. | $231.01 | 2023-2024 | Strensiq |
| Aurinia Pharma U.S., INC. | $149.45 | 2022-2024 | Lupkynis |
| Gilead Sciences, INC. | $121.83 | 2024 | Vemlidy |
| Astrazeneca Pharmaceuticals LP | $116.26 | 2022-2025 | |
| Pfizer INC. | $96.40 | 2023-2024 | |
| Abiomed | $89.11 | 2024 | Impella |
| Janssen Biotech, INC. | $82.53 | 2023-2024 | Tremfya |
| Abbott Laboratories | $64.84 | 2021-2025 | Na |
| Lilly USA, LLC | $51.64 | 2024 | Taltz, Zepbound |
| Organon LLC | $48.84 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $34.53 | 2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.60 | 2024 | Cyltezo |
| Sandoz INC. | $27.37 | 2024 | Hyrimoz |
| Biocon Biologics INC | $25.59 | 2024 | Hulio |
| Fresenius Kabi USA, LLC | $25.00 | 2024 | |
| Horizon Therapeutics Plc | $23.16 | 2022 | |
| Alvogen INC | $14.41 | 2024 | Teriparatide |
| E.R. Squibb & Sons, L.L.C. | $13.72 | 2024 | Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.